Topic resource collection
Approved comparison material connected to this topic.
774 resourcesRead both sides
BPC-157 (research peptide) VEGF upregulation, eNOS activation, MMP inhibition Promotes endothelial repair, reduces matrix degradation, improves venous tone Unknown. No long-term human data available Most promising for addressing …
BPC-157 VEGF upregulation, NO pathway modulation, mucosal healing Accelerated colonic anastomosis healing, reduced inflammatory infiltrates in colitis models (Journal of Physiology-Paris) Intraperitoneal, oral, topical Limited hu…
Ibuprofen (NSAID) COX-1/COX-2 inhibition Prostaglandin synthesis blockade 30–60 minutes 1.8–2 hours Does not address uterine ischemia or smooth muscle dysfunction; gastrointestinal erosion risk with chronic use BPC-157 eNOS upreg…
BPC-157 VEGF receptor upregulation, NO synthesis, FAK-paxillin pathway activation 10–20mcg/kg daily (animal models) Subcutaneous injection Rodent studies, one small human case series Strong mechanistic rationale; human clinical d…
Evidence Level Multiple published wound healing studies in tendon, ligament, dermal models Established cell migration and anti-inflammatory data, primarily in soft tissue injury Strong collagen remodeling evidence, widely studied…
BPC-157 Upregulates VEGF and angiogenesis in hypoxic tissue; increases capillary density at injury site 200–500 mcg/day subcutaneous near injury site for 4–8 weeks Subcutaneous injection into thenar eminence or web space 3–4 week…
Thymalin Thymic immune regulation; modulates T-cell activity and suppresses inflammatory cytokines (IL-6, TNF-α) Observational study (St. Petersburg Institute). 30% cytokine reduction, 40–50% hot flash frequency reduction over 8 …
BPC-157 VEGF upregulation, angiogenesis Promotes new capillary formation in ischemic tissue. Addresses progressive microvascular damage Preclinical animal models; no human Raynaud's trials Requires daily subcutaneous injection; e…
BPC-157 VEGF upregulation, eNOS activation, endothelial repair 200–500 mcg/day subcutaneous 4–6 hours Preclinical animal models show 40% improvement in blood flow recovery vs controls Strongest mechanistic evidence for direct ang…
The table below compares the three leading research peptides for REM architecture restoration. Each compound operates through a distinct neurochemical mechanism. Understanding the pathway differences is critical to selecting the …
P21 BDNF upregulation, hippocampal neurogenesis No REM extension. Enhances consolidation efficiency during existing REM periods High. Improved narrative coherence and next-day recall without sleep fragmentation 10–20mg subcutaneo…
Before selecting a peptide protocol, understand what each compound does at the molecular level and how those mechanisms apply to fibrocartilage structure. BPC-157 VEGF upregulation, angiogenesis Extends vascular penetration into …
Thymalin Thymic immune modulation, cytokine regulation Reduces neuroinflammation driven by IL-6, TNF-alpha at trigeminal junction Animal models + immune disorder trials Requires reconstitution, subcutaneous injection, typically 5…
Thymosin Beta-4 (TB-4) Downregulates TGF-β1, inhibits mast cell degranulation, promotes organized angiogenesis Active (early-stage) Reduced keloid fibroblast proliferation by 40% at 100 μg/mL (Journal of Investigative Dermatology…
Before integrating any peptide into a chronic insomnia protocol, understanding mechanism specificity and evidence quality is essential. DSIP (Delta Sleep-Inducing Peptide) Modulates slow-wave sleep architecture; normalizes HPA-ax…
Thymalin Immunomodulation via thymic peptide bioregulation Restores CD4+/CD8+ T-cell balance and increases regulatory T-cell populations that suppress autoimmune inflammation 5–10mg daily subcutaneous for 10–20 days Preclinical a…
BPC-157 VEGF-mediated angiogenesis, collagen organization at injury site 200–400 mcg daily (human equivalent dose from animal models) Local subcutaneous or intramuscular near injury 30–40% reduction in healing time in animal tend…
Before reviewing specific peptides, understand that this comparison evaluates research-grade compounds based on preclinical evidence and proposed mechanisms—not clinical trial outcomes in celiac patients. None of these peptides a…
Thymalin Immune modulation via thymic peptide bioregulation Reduces hepatic inflammation that drives cholesterol synthesis 5–10mg subcutaneous 2–3x/week for 8–12 weeks 6–10 weeks for lipid panel changes Best for individuals with …
Collagen Peptides (Hydrolyzed) 2,000–5,000 Da Negligible (enzymatic degradation prevents intact transfer) 3 observational studies, n=127 total, no adverse infant outcomes documented Safe for use. Select marine or bovine sources w…